reviewTop 10% cited
Does levodopa slow or hasten the rate of progression of Parkinson’s disease?
Journal of Neurology · 2005 · Vol. 252(S4) · pp. iv37–iv42
Stanley Fahn✉(Columbia University)and the Parkinson Study Group
Parkinson's Disease Mechanisms and TreatmentsNeurological disorders and treatmentsNuclear Receptors and SignalingLevodopaMedicineCarbidopaParkinson's diseaseNeurologyPlaceboClinical trialSelegilineInternal medicineRandomized controlled trial
MeSH terms
Antiparkinson AgentsBrainCarbidopaDose-Response Relationship, DrugDouble-Blind MethodHumansLevodopaParkinson DiseaseRandomized Controlled Trials as TopicTreatment OutcomeDisease Progression
Citations
349
FWCI
10.69
field-weighted impact
References
35
Percentile
99%
vs. same field & year
Citations per year
Cited by
Biomarkers of Parkinson’s disease: Present and future
Metabolism · 2014 · 399 citations
Axon degeneration in Parkinson's disease
Experimental Neurology · 2012 · 493 citations
Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease
British Journal of Pharmacology · 2011 · 734 citations
References
Parkinson's Disease
Neuron · 2003 · 5,394 citations
Effects of Coenzyme Q10 in Early Parkinson Disease
Archives of Neurology · 2002 · 968 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.